Department of Psychiatry, Manchester University, UK
Department of Cardiology, Manchester Royal Infirmary, UK
Department of Psychiatry, Manchester University, UK
Correspondence: Chris Dickens, Department of Psychiatry, Rawnsley Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. Tel: +44 (0)161 276 5386; fax: +44 (0)161 273 2135; email: chris.dickens{at}manchester.ac.uk
Declaration of interest F.H.C. has performed consultancy work for Ely Lilly in a field unconnected with the current study. There are no other conflicts of interest to declare.
|
|
|---|
Aims To quantify the adverse influence of depression and anxiety, assessed at the time of first myocardial infarction and 6 months later, on the physical aspect of HRQoL 12 months after the infarction.
Method In all, 260 in-patients, admitted following first myocardial infarction, completed the Hospital Anxiety and Depression Scale and the Medical Outcomes Study SF36 assessment before discharge and at 6- and 12-month follow-up.
Results Depression and anxiety 6 months after myocardial infarction predicted subsequent impairment in the physical aspects of HRQoL (attributable adjusted R2=9%, P<0.0005). These negative effects of depression and anxiety on outcome were mediated by feelings of fatigue. Depression and anxiety present before myocardial infarction did not predict HRQoL 12 months after myocardial infarction.
Conclusions Detection and treatment of depression and anxiety following myocardial infarction improve the patients health-related quality of life.
|
|
|---|
|
|
|---|
The study was approved by the relevant local research ethics committees.
Sample
Consecutive patients admitted to four inner-city hospitals with suspected
myocardial infarction were screened for this study, on average 3.6 (s.d.=3.3)
days after admission. Individuals were recruited if they had no history of
previous myocardial infarction, were aged less than 80 years and met World
Health Organization criteria for myocardial infarction
(Gutzwiller, 1994). Two of the
following were required: history of typical chest pain, characteristic
echocardiogram changes, a serial rise in cardiac enzyme creatine phosphokinase
(CPK). People with severe mental illness (including severe depression with
suicidal ideas) were excluded from the study. Written, informed consent was
provided by participants after the procedures involved in the study had been
fully explained.
Participants received treatment as usual, as determined by the attending hospital physician and primary care doctors. As this was an observational study, participants did not receive any additional therapy (e.g. antidepressants) based on their research assessments.
Baseline assessments
We recorded age, gender (male=1, female=2), ethnicity (White=1, Black and
minority ethnic=0), marital status (single: yes=1, no=0), years of education,
smoking history (past or current smoker=1, never smoked=0), past psychiatric
history (yes=1, 1, no=0) and comorbid illnesses for which participants were
receiving regular treatment (for each illness yes=1, no=0). Socioeconomic
status, based on current or latest employment, was categorised into high or
low according to the criteria of Goldthorpe and Hope
(Goldthorpe & Hope, 1974),
(lower status=1, higher status=2). Serum cholesterol was measured during
admission.
Details of the myocardial infarction were recorded from the notes, with discussion with the attending cardiologist if clarification was required. We recorded site of infarction as determined by echocardiogram, categorised as anterior (including anterior, anterolateral, anteroseptal and apical myocardial infarctions, scored as 1) or other (scored as 2). Details of treatment, including reperfusion therapy, surgical intervention during index admission (angioplasty or coronary artery bypass graft) and discharge medication were also noted. We used three measures of severity of myocardial infarction. The Killip class, a 4-point scale, rated left ventricular function based on the presence of pulmonary rales, S3 gallop rhythm and peripheral hypoperfusion, with high scores representing worse function (Killip & Kimball, 1967). Creatine phosphokinase levels were measured on admission and on 2 subsequent days as an indication of the extent of myocardial damage. Finally, left ventricular ejection fraction measures (using echocardiogram) were recorded for 217 patients.
Anxiety and depression were assessed using the self-rated, 14-item Hospital Anxiety and Depression Scale (HADS), which scores the severity of the symptoms of anxiety (scored 0 to 21) and depression (scored 0 to 21). This measure was developed specifically for medically ill populations, and excludes bodily symptoms such as sleep disturbance, fatigue and pain that may be owing to physical illness (Zigmond & Snaith, 1983). The HADS has been widely used in people with medical illnesses, including myocardial infarction, and its factor structure has been confirmed (Herrmann, 1997; Herrmann et al, 1998; Mayou et al, 2000). At baseline, participants were instructed to complete the questionnaire to reflect their mood during the week before myocardial infarction, in order to avoid recording mood changes that occur as immediate reactions to the infarction and during time spent on the coronary care unit. In addition to using HADS subscores to measure severity of depression and anxiety, a HADS total score of 17 or above was taken to indicate probable major depressive disorder, as we have validated this score against a standardised research interview (Dickens et al, 2004b). We did not aim to measure distress in the period immediately after infarction, and we have recorded the fact that HADS scores rated for the days following admission were significantly higher than those rated for the week before, which were used in this report (Dickens et al, 2004b).
Participants completed the Illness Perceptions Questionnaire (Weinman et al, 1996), which assesses patients perception of their illness in terms of:
This scale has been used previously for people who have experienced myocardial infarction (Petrie et al, 1996, 2002).
We used the self-reported Medical Outcomes Study SF36 (Ware & Sherbourne, 1992) to assess both the physical and mental aspects of HRQoL at baseline, 6 months and 12 months following myocardial infarction. The SF36 is a generic measure of HRQoL that provides scores on eight sub-scales, reflecting functioning over the month preceding the assessment. The SF36 has been well validated in populations with coronary heart disease (Failde & Ramos, 2000; Morrin et al, 2000; Rumsfeld & Ho, 2005). We deliberately chose a generic measure of HRQoL, as opposed to a cardiac-specific measure, as our main outcome; people after myocardial infarction frequently experience multiple health problems, and we wanted a measure that was sensitive to the impact of noncardiac illnesses on HRQoL. A cardiac-specific measure of HRQoL would be less sensitive to such non-cardiac illnesses.
We used the SF36 Physical Component Score (PCS) as the primary outcome measure, because it has greater sensitivity to change over the original eight scales of the SF36, involves fewer statistical comparisons and eliminates floor and ceiling effects (Ware et al, 1994, 1995). The PCS was derived from four sub-scales (physical function, role limitation, physical pain and health perceptions), using the method described by Ware and colleagues (Ware et al, 1994). The PCS is standardised to the general population (mean score, 50: standard deviation, 10), with high scores representing higher levels of functioning. A change on the PCS of between 3 and 5 (equivalent to 0.3 to 0.5 of the standard deviation) is considered to be clinically significant (Beck et al, 2001). We did not use the mental component score as an outcome measure, as its items overlap with those of the HADS; however, we did use the SF36 energy and vitality sub-scale as a measure of fatigue, for the purposes of the mediator analyses.
Follow-up assessment
The HADS, Illness Perceptions and SF36 questionnaires were mailed to
our study participants at 6 and 12 months following myocardial infarction. At
12 months, participants were asked whether they experienced chest pain and, if
appropriate, whether they had returned to work. They were also asked to
complete the Seattle Angina Questionnaire
(Spertus et al,
1995). This 19-item self-rated questionnaire assesses cardiac
health status as perceived by the patient on 5 scales: physical limitations
owing to chest pain, anginal stability, anginal frequency, treatment
satisfaction and perceived burden of cardiac illness.
Participants were also asked to give details of hospital attendances during followup period (dates, hospitals attended and nature of health problem). Hospital attendances were verified by inspection of the appropriate hospital records, during which we confirmed whether participants had experienced any significant cardiac events during the 12 months following the myocardial infarction. These were defined as admissions to hospital or visits to accident and emergency departments with an acute cardiac problem, confirmed by investigations, e.g. chest pain associated with acute changes on echocardiogram. Both angioplasty and coronary artery bypass graft following an acute deterioration in cardiological state during the follow-up period were included.
Statistics
We used hierarchical multiple regression techniques to identify, at
baseline and 6 months, variables that contributed to SF36 PCS at 12
months after myocardial infarction, which was the dependent variable. The
following independent variables were entered in blocks in the order presented
below.
Block 1 (socio-demographic factors): age, gender, marital status (widowed, divorced, separated or other), education (more or less than 12 years), socio-economic status and baseline SF36 PCS.
Block 2 (comorbid, non-cardiac illnesses): current rheumatic, respiratory, gastrointestinal or other disorder (including neurological, renal, cerebrovascular disease or endocrine disorder other than diabetes).
Block 3 (cardiac factors): ongoing risk factors for further coronary heart disease (diabetes, serum cholesterol, hypertension, previous cardiac disease, previous or current smoking v. never), measures of severity of index myocardial infarction (Killip class, CPK), site of infarction, use of thrombolysis or surgical intervention during index admission, cardiac medication on discharge and cardiac events during subsequent 12 months.
Block 4 (anxiety and depression): HADS anxiety and depression scores at baseline.
This analysis was then repeated using block 4 depression and anxiety scores recorded 6 months after infarction, in place of the same scores measured at baseline.
Collinearity diagnostics were performed and showed that, although the independent variables were associated, the degree of association was not so great as to threaten the reliability of the regression analyses (variance inflation factors all < 2.5, tolerances all > 0.4) (Field, 2000).
In order to check that we had adjusted adequately for cardiac function, the analyses were repeated including the subgroup of 217 participants who had undergone echocardiogram, with left ventricular ejection fraction (categorised as < 30%, 3050% and > 50%) entered into the regression equation in place of Killip class. In addition, we assessed whether chest pain, fatigue (energy and vitality sub-scale of the SF36), illness perceptions or self-rated cardiac health status at 12-month follow-up could act as possible mediators of any association between depression/anxiety and SF36 PCS at 12 months. These potential mediators were added after block 3, to see whether the subsequent contribution of depression/anxiety to the model was reduced, according to the method of Baron & Kenny (1986).
Statistics were performed using the Statistical Package for the Social Sciences for Windows, version 11.5.0 (2002).
|
|
|---|
In all, 199 participants (63%) had comorbid, non-cardiac illnesses, most commonly rheumatic (32%), respiratory (15%) or gastrointestinal disorders (13%). The HADS depression score at baseline was 4.9 (s.d.=4.0), and anxiety score was 7.4 (s.d.=4.9). The mean SF36 PCS score at baseline was 43.2 (s.d.=12.3).
Follow-up assessment
At 6 months, follow-up data were collected for 268 participants. Mean HADS
depression score at 6 months was 5.6 (s.d.=4.0) and mean anxiety score was 7.7
(s.d.=4.6). Mean SF36 PCS score was 39.0 (s.d.=11.3).
At 12-month follow-up, 16 patients had died and follow-up data were collected from 260 (83% of original sample; 87% of survivors). Participants who did not complete follow-up were significantly younger than those who did, i.e. 53.3 (s.d.=10.4) v. 57.9 (s.d.=11.3) years, respectively, more likely to have low socioeconomic status (73.7% v. 54.3%, respectively), and less likely to have received aspirin (90% v. 96%, respectively). There were no statistically significant differences in other demographic variables, medical history, severity of myocardial infarction, depression and anxiety scores or SF36 PCS between those who completed assessments and those who dropped out of the study.
Mean HADS depression score at 12 months was 5.4 (s.d.=4.2) and mean anxiety score was 7.5 (s.d.=4.7). The mean SF36 PCS score at 12-month follow-up was 40.4 (s.d.=11.9); participants who were depressed at this time had lower PCS scores than those who were not, i.e. mean scores=32.7 (s.d.=9.9) v. 43.8 (s.d.=11.1), respectively, t=7.8, P<0.0005.
At the time of their myocardial infarction, 137 patients were employed (part time or full time). Their mean PCS at baseline (adjusted for age and gender) was 48.7 (s.e.m.=0.86) compared with 31.8 (s.e.m.=1.9) for those on sick leave (n=29, F=43.0, P<0.0005). Of those employed at baseline, 3 died during the subsequent 12 months, and we collected complete follow-up data on 100 of the remainder (75%). For the 66 who had returned to work at 12-month follow-up, the mean PCS at follow-up (adjusted for the variables that predicted PCS at 12 months listed in Table 1) was 46.5 (s.e.m.=1.3) and for the 30 who had not returned to work, it was 39.5 (s.e.m.=1.7, F=9.1, P=0.003).
|
View this table: [in a new window] | Table 1 Regression model: predictors of Medical Outcomes Study SF36 physical component score 12 months1 after myocardial infarction |
Predictors of SF36 PCS at 12-month follow-up
The variables that were independently associated with low SF36 PCS
at 12-month follow-up are shown in Table
1. Addition of the cardiac variables (block 3) increased the
proportion of the variance accounted for (adjusted R2) by
5%, and further addition of depression and anxiety scores at 6 months (block
4) increased the adjusted R2 by a further 9%
(F-change=10.5, P<0.0005). Anxiety and depression
measured at baseline and reflecting patient mood in the weeks before first
myocardial infarction did not contribute significantly to the regression model
after controlling for demographic and medical details
(F-change=0.89).
Repeating the above analyses using left ventricular ejection fraction in place of Killip class (n=217) did not change our findings. Depression and anxiety at 6 months continued to contribute significantly to PCS at 12 months (adjusted R2 attributable to block 4=11%, F-change=18.6, P<0.0005).
Assessment of potential mediator variables
Reported chest pain, SF36 energy and vitality scores, Illness
Perceptions Questionnaire and Seattle Angina Questionnaire scores at 12 months
were potential mediators, as they all showed significant univariate
associations with both depression and anxiety at baseline and 6 months and
with PCS at 12 months after myocardial infarction.
When chest pain was entered as a potential mediator, the
R2 for depression and anxiety at 6 months decreased from
9% to 5.0%, but the R2 attributable to depression and
anxiety remained significant at P<0.0005. When SF36 energy
and vitality score was added, the R2 for depression and
anxiety decreased to 0% (P=0.37). Addition of the Illness Perceptions
Questionnaire sub-scores, either singly or together, reduced the
R2 that was independently attributable to the depression
and anxiety measures, although in all models the contributions of depression
and anxiety remained significant (P
0.01). Similarly, addition of
the scores from the Seattle Angina Questionnaire reduced the magnitude of the
R2 attributable to anxiety and depression, although it
remained significant (all P
0.002).
The effects of changing depression on SF36 PCS
To clarify the effect of depression severity changing between baseline and
12-month follow-up, we compared changes in the SF36 PCS of 38
participants who were not depressed at baseline but who became depressed
during follow-up, with those of 143 participants who remained undepressed
throughout the study period, using HADS total of
17 to indicate
depression. The HADS depression scores of these two groups at baseline were
3.2 (2.2) and 2.7 (2.5), respectively, (t=1.3,
P=0.2), confirming the non-depressed status of both groups at
baseline. There was no significant difference in SF36 PCS at baseline
between these two groups: scores were 42.1 (12.8) and 45.5 (11.5),
respectively (t=1.6, P=0.12). The HADS depression score at
12 months for individuals who became depressed was 10.0 (3.2) whereas for
those who remained nondepressed it was 3.0 (2.2), (t=15.6,
P<0.0005). The SF36 PCS for these groups were 30.9 (7.4)
and 44.1 (10.7) (t=8.8, P<0.0005).
|
|
|---|
Our method has a number of strengths, according to the quality criteria used in the systematic review of Sørensenf et al (2005). First, we screened a consecutive series of patients presenting with first myocardial infarction, and managed to recruit and follow up a high proportion of eligible individuals. Second, we included only people who had not experienced previous myocardial infarction, to avoid any confounding effect of previous infarction on the association between depression and later impairment of HRQoL. Third, we used valid and widely recognised measures of depressive symptoms and HRQoL that were appropriate for our population, and we used the same measures over three waves of assessment. In our regression analyses, we controlled for a wider range of potential confounders than any previous study, including the effects of cardiac and non-cardiac illness, and for baseline SF36 PCS before assessing the contribution of anxiety and depression. Furthermore, we assessed rigorously the cardiac status of participants, particularly with regard to the severity of myocardial infarction, using a range of clinical and laboratory techniques. Thus we can be confident that our assessment of the contribution of anxiety and depression to subsequent HRQoL was conservative.
Our study has some weaknesses. Our assessments of depression and HRQoL were retrospective, making them vulnerable to recall bias. However, we had validated the HADS administered in this way against a standardised psychiatric interview that asked in detail about each depressive symptom (sleep loss, appetite difficulty, mood, etc.) for the month before the myocardial infarction (Dickens et al, 2004b). We were also able to show the validity of the SF36 in relation to employment status. Furthermore, our findings are supported by those of a truly prospective study that showed that onset of coronary heart disease led to deterioration of physical function and role performance, when it was associated with increased anxiety and depression (van Jaarsveld et al, 2002).
Psychiatrists will be familiar with the impairment in the mental component of the SF36 that occurs with depression, but we have shown that when depression is concurrent with physical illness there is also a reduction of the physical component. The low SF36 PCS score of participants who were depressed at 12 months represented very marked impairment, with a mean score one standard deviation lower (more impaired) than that for non-depressed participants and nearly two standard deviations lower than the score for the general population.
We have shown previously that fatigue is associated with depression in patients presenting with myocardial infarction (McGowan et al, 2004). This current report indicates that this fatigue mediated the observed association between depression and HRQoL. There are a number of mechanisms by which fatigue might be associated with impairment in HRQoL. Fatigue may occur as the direct result of depression, and may be mistaken for a symptom of ongoing cardiac problems, thus leading to impaired HRQoL by virtue of increasing symptom load. Furthermore, fatigue following myocardial infarction may lead to deconditioning (or possibly, failure to rehabilitate) through reduced tolerance of physical activity, with consequent loss of physical function (Lavoie et al, 2004).
It is interesting that depression and anxiety that preceded myocardial infarction did not predict impairment in HRQoL 12 months following infarction, whereas depression and anxiety recorded 6 months after infarction did so. We have shown previously, however, that there are considerable changes in depression scores over the period following myocardial infarction; 45% of those depressed at baseline improved during the 12 months following infarction, whereas 21% of those not depressed at baseline developed depression during follow-up (Dickens et al, 2004a). It is possible that these changes in depression reduced the effect of pre-infarction depression on HRQoL 12 months after infarction in our regression analyses.
Our findings have considerable implications for clinical practice. Although depression is common following myocardial infarction, the people recruited for our study very rarely attracted treatment. This may represent hesitancy on the part of general practitioners and other doctors to prescribe antidepressants after myocardial infarction, even though this is generally safe (Glassman et al, 2002). It is more likely that depression is rarely recognised and treated in the physically ill, even though such treatment is effective (Gill & Hatcher, 1999).
Psychiatrists should be prepared to treat, or advise general practitioners to treat, depression using antidepressant and cognitivebehavioural therapy. Our findings indicate the importance of detecting and treating depression and anxiety, since it would be expected that reducing depression and anxiety would lead to improved quality of life and reduction in days of restricted activity and days missed from work (Kisely & Simon, 2005). This remains to be demonstrated in a clinical trial, however (Simon et al, 1998).
|
|
|---|
|
|
|---|
Related articles in BJP:
This article has been cited by other articles:
![]() |
S. F. Auyeung, Q. Long, E. B. Royster, S. Murthy, M. D McNutt, D. Lawson, A. Miller, A. Manatunga, and D. L Musselman Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy Clinical Trials, October 1, 2009; 6(5): 480 - 490. [Abstract] [PDF] |
||||
![]() |
M Elovainio, M Kivimaki, J E Ferrie, D Gimeno, R De Vogli, M Virtanen, J Vahtera, E J Brunner, M G Marmot, and A Singh-Manoux Physical and cognitive function in midlife: reciprocal effects? A 5-year follow-up of the Whitehall II study J Epidemiol Community Health, June 1, 2009; 63(6): 468 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
Post-Myocardial Infarction Depression Clinical Pra AAFP Guideline for the Detection and Management of Post-Myocardial Infarction Depression Ann. Fam. Med, January 1, 2009; 7(1): 71 - 79. [Full Text] [PDF] |
||||
![]() |
H. Seivewright, J. Green, P. Salkovskis, B. Barrett, U. Nur, and P. Tyrer Cognitive-behavioural therapy for health anxiety in a genitourinary medicine clinic: randomised controlled trial The British Journal of Psychiatry, October 1, 2008; 193(4): 332 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. DeVon, C. J. Ryan, A. L. Ochs, and M. Shapiro Symptoms Across the Continuum of Acute Coronary Syndromes: Differences Between Women and Men Am. J. Crit. Care., January 1, 2008; 17(1): 14 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dickens, L. McGowan, C. Percival, B. Tomenson, L. Cotter, A. Heagerty, and F. Creed Depression Is a Risk Factor for Mortality After Myocardial Infarction: Fact or Artifact? J. Am. Coll. Cardiol., May 8, 2007; 49(18): 1834 - 1840. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. de Jonge and J. Ormel Depression and anxiety after myocardial infarction The British Journal of Psychiatry, March 1, 2007; 190(3): 272 - 273. [Full Text] [PDF] |
||||
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||